Clinical Trial Update: A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing trastuzumab-deruxtecan to standard-of-care in early breast cancer patients with molecular relapse; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Prof. Wolfgang Janni | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING